

**Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab)**  
**Recombinant Antibody**  
**Catalog # APR10639**

**Specification**

**Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab) - Product Information**

Application	FC, Kinetics, Animal Model
Primary Accession	<a href="#">O95436</a>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.66 KDa

**Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab) - Additional Information**

**Target/Specificity**  
NaPi2b / SLC34A2

**Endotoxin**  
< 0.001EU/ µg, determined by LAL method.

**Conjugation**  
Unconjugated

**Expression system**  
CHO Cell

**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

**Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab) - Protein Information**

**Name** SLC34A2

**Function**  
Involved in actively transporting phosphate into cells via Na(+) cotransport.

**Cellular Location**  
Apical cell membrane {ECO:0000250|UniProtKB:Q9DBP0}; Multi-pass membrane protein.  
Note=Localized at the brush border membranes of enterocytes.  
{ECO:0000250|UniProtKB:Q9DBP0}


**Tissue Location**  
Highly expressed in lung. Also detected in pancreas, kidney, small intestine, ovary, testis, prostate and mammary gland. In lung, it is found in alveolar type II cells but not in bronchiolar epithelium.

## Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

## Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab) - Images



Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab) is more than 100%, determined by SEC-HPLC.